Search research articles
Contact Us
Filters
Showing results (901-910 of 968) with videos related to
Page
of 97
Sort By:
Circulation. Cardiovascular Imaging
|
May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Paolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology
|
June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Toshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
American Journal of Clinical Pathology
|
September 2, 2023
Superior detection rate of plasma cell FISH using FACS-FISH
Marie-France Gagnon, Sally M Midthun, James A Fangel, et al.
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation
Wei Li, Kimberly K Crouse, Jennifer Alley, et al.
Lancet (London, England)
|
January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
David Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Blood
|
January 24, 2004
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Angela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Blood Cancer Journal
|
January 9, 2020
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
Rahma Warsame, Betsy LaPlant, Shaji K Kumar, et al.
Page
of 97
Search research articles
Search
Showing results (901-910 of 968) with videos related to
Sort By:
Page
of 97
Circulation. Cardiovascular Imaging
|
May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Paolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
American Journal of Hematology
|
June 2, 2017
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Toshi Ghosh, Wilson I Gonsalves, Dragan Jevremovic, et al.
American Journal of Clinical Pathology
|
September 2, 2023
Superior detection rate of plasma cell FISH using FACS-FISH
Marie-France Gagnon, Sally M Midthun, James A Fangel, et al.
Transplantation and Cellular Therapy
|
August 8, 2022
Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
Mohammad Ebraheem, Shaji K Kumar, Angela Dispenzieri, et al.
Annals of Hematology
|
April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
Jonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 4, 2023
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6<sup>+</sup> T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation
Wei Li, Kimberly K Crouse, Jennifer Alley, et al.
Lancet (London, England)
|
January 11, 2025
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
David Fiorentino, Aaron R Mangold, Victoria P Werth, et al.
Blood
|
January 24, 2004
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Angela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Blood Cancer Journal
|
January 9, 2020
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
Rahma Warsame, Betsy LaPlant, Shaji K Kumar, et al.
Page
of 97